ABT · Abbott Laboratories · Stock research

Current Thesis

Abbott spent the first half of 2026 being de-rated for an acquisition. The Exact Sciences purchase closed 2026-03-23 at $105/share cash — roughly $21B in equity and about $23B enterprise value including ~$1.8B of assumed net debt — and carried approximately $0.20 of FY26 adjusted-EPS dilution. Stacked on a weak respiratory season and China volume-based procurement in Core Lab Diagnostics, that took the stock from a 52-week high of $137.49 to an intraday low of $81.97 on 2026-05-11 (close $82.56).

The 2026-07-16 Q2 print was the first hard evidence the de-rating had overshot. Sales of $12,593M (+13.0% reported, +4.8% comparable) against roughly $12.48B consensus, adjusted diluted EPS of $1.31 against $1.28, GAAP diluted EPS $0.53, and FY26 adjusted EPS guidance lifted to $5.45–$5.60 from $5.38–$5.58. Shares gained more than 10% in that session. Eleven days later, on 2026-07-27, the FDA approved Freenome's SimpleScreen CRC blood test, which Abbott exclusively commercializes in the US from fall 2026 in exchange for a $100M milestone payment to Freenome — putting stool-based (Cologuard) and blood-based colorectal screening under the same roof.

The narrative leg on offer is the unwind of a deal-driven multiple compression, with cardiac devices funding the ramp in the acquired diagnostics assets. Medical Devices grew 8.4% comparable to $5,853M in Q2, electrophysiology +13.4%, and Volt pulsed-field ablation was FDA-approved on 2025-12-22.

Bullish and bearish views on Abbott Laboratories

The model's bull view on Abbott Laboratories (ABT), in brief: Q2 2026 double beat (2026-07-16) — sales $12,593M, +13.0% reported and +4.8% comparable, against roughly $12.48B consensus; adjusted diluted EPS $1.31 against $1.28. The bear view: The full-year guide implies a step-up Q2 did not deliver. Both cases follow in full.

Bull Case

• Q2 2026 double beat (2026-07-16) — sales $12,593M, +13.0% reported and +4.8% comparable, against roughly $12.48B consensus; adjusted diluted EPS $1.31 against $1.28.
• First guidance raise of 2026 — the FY26 adjusted-EPS range went $5.55–$5.80.38–$5.58 at the 2026-04-16 Q1 report → raised to $5.45–$5.60 on 2026-07-16. Q3 2026 adjusted EPS guided $1.38–$1.46.
• The cardiac line is carrying growth — Medical Devices $5,853M, +8.4% comparable; electrophysiology +13.4%; structural heart +5.7%; CGM +9.5% comparable with FreeStyle Libre quarterly sales above $2B (Q2 2026 release and call).
• The acquired asset is compounding — cancer diagnostics revenue +13% with Cologuard growing mid-teens; on the 2026-07-16 call management attributed expected H2 acceleration to health systems running care-gap programs tied to HEDIS and CMS Star ratings.
• 2026-07-27 FDA approval, SimpleScreen CRC — the PREEMPT CRC study enrolled more than 48,000 asymptomatic average-risk adults across 200+ sites; 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. US launch scheduled for fall 2026.
• Insiders bought the drawdown — director John Stratton bought 2,000 shares at $86.82 on 2026-05-07 (Form 4 filings).
• Dated pipeline steps — Amulet 360 left atrial appendage FDA submission completed May 2026; TECTONIC coronary intravascular lithotripsy pivotal enrollment completed April 2026.

Bear Case

• The full-year guide implies a step-up Q2 did not deliver. FY26 comparable sales growth was reaffirmed at 6.5%–7.5% while Q2 comparable growth printed 4.8%. The second half has to carry that difference.
• Nutrition is shrinking — $2,144M in Q2 2026, -3.6% comparable, the only division in outright decline.
• Diagnostics is barely growing — $3,092M, +2.9% comparable, with China volume-based procurement still pressuring Core Lab and management holding a cautious China stance since the 2026-04-16 Q1 call.
• NEC litigation is open-ended — 810 preterm-formula cases pending in MDL 3026 before Judge Rebecca Pallmeyer (N.D. Ill.) as of July 2026. A Chicago jury awarded $53M compensatory on 2026-04-09 and $17M punitive on 2026-04-10; a Missouri appeals court declined on 2026-06-24 to refer the $495M 2024 verdict to that state's supreme court.
• The upside case is already the consensus case — mean price target $118.42 across 27 analysts against a $105.70 close on 2026-07-31, and UBS cut its target from $135 to $125 on 2026-07-28 while keeping a Buy rating.
• Valuation is not distressed — trailing P/E 34.20, forward P/E 18.23, market cap $182.90B at the 2026-07-31 close.

Setup & Price Structure

Close $105.70 on 2026-07-31, inside a 52-week range of $81.97–$137.49. The recovery path is dated: $88.41 on 2026-06-18, $100.68 on 2026-07-17 after the Q2 gap, $105.70 on 2026-07-31.

Moving averages at 2026-07-31 (Barchart): 20-day $99.08, 50-day $93.30, 100-day $95.34, 200-day $108.35. Price sits above the three shorter averages and below the 200-day, which is the one overhead line that matters at these levels. 14-day RSI 66.77.

Life-cycle: ACCELERATING. The dates carry the label — a greater-than-10% single-session move on 2026-07-16, eight sell-side target actions on 2026-07-17 (six raises: BTIG to $134, JPM to $120, Evercore to $120, Piper Sandler to $118, Citigroup to $112, Wells Fargo to $112; RBC maintained $130 and TD Cowen maintained $115), and a fresh FDA approval on 2026-07-27. Attention is returning to a name the market discarded between March and May.

Crowding and positioning observables: RSI 66.77 with price well above a 20-day at $99.08; the 200-day at $108.35 not yet reclaimed; target dispersion of $112–$134 from the 2026-07-17 cluster around a $118.42 mean; UBS trimming $135 to $125 into strength on 2026-07-28; no scheduled earnings date until the Q3 report expected mid-October; 2026 insider activity skewed to open-market buying at $86.82–$91.50 in April and May against an EVP open-market sale of 613 shares at $115.58 on 2026-03-02.

Catalyst Calendar (next 30 days)

• 2026-08-17 — quarterly dividend of $0.63/share payable (record date 2026-07-15), annualizing $2.52 against a 2.38% yield at the 2026-07-31 close.
• 2026-08-28 to 2026-08-31 — ESC Congress 2026, Messe München. Late-breaking cardiology data frames the pulsed-field ablation contest against Boston Scientific, Medtronic and J&J — the line that produced Q2's 13.4% electrophysiology growth.
• ~2026-10-01 (est.) — SimpleScreen CRC US commercial launch, described as "fall 2026" in the 2026-07-27 approval release. First pricing and reimbursement datapoints.
• ~2026-10-15 (est.) — Q3 2026 results against the $1.38–$1.46 adjusted-EPS guide and the reaffirmed 6.5%–7.5% FY comparable range.

No Abbott-specific regulatory decision or guidance event is confirmed inside the 30-day window. The Amulet 360 FDA submission completed in May 2026 has no published decision date.

What Would Change Our Mind

The structure that has to hold is the 2026-07-16 repricing gap. Price left a shelf in the low-to-high $90s when it moved on the Q2 beat — it traded $88.41 as recently as 2026-06-18 and closed $100.68 on 2026-07-17. A return into that shelf would mean the market read the raise as a one-quarter consolidation artifact rather than a change in the underlying rate. Concretely, a weekly close below $95 surrenders that gap and the reclaimed 50-day average and puts price back inside the range it occupied from March through mid-July.

Two non-price conditions carry comparable weight. If the FY26 comparable range of 6.5%–7.5% is trimmed at the October report instead of reaffirmed, the second-half acceleration that justified the July move is gone and Q2's 4.8% becomes the run rate. If the 200-day at $108.35 is tested and rejected without a close through it while the shorter averages flatten, the life-cycle label moves from ACCELERATING to MATURING regardless of what the prints say.

A fresh adverse NEC verdict of material size, or a litigation reserve disclosed against MDL 3026, would reopen the discount the stock carried through May.

Correlation Notes

• US procedure volumes are the shared factor across large-cap medtech. Intuitive Surgical fell 11% on 2026-07-17 after warning that insurance changes could slow US procedure growth; Abbott closed $100.68 that same session on its own beat. Medical Devices at +8.4% comparable rests on the same procedure base, so that commentary spreading through Q3 medtech reports is a read-through risk.
• Pulsed-field ablation is a share fight, not a rising tide. Boston Scientific, Medtronic and J&J were in the US PFA market before Abbott's 2025-12-22 Volt approval, so competitor electrophysiology disclosures bear directly on whether ABT's 13.4% EP growth persists.
• Cancer diagnostics now links ABT to the screening complex through reimbursement and guideline decisions rather than through procedure counts — coverage determinations for blood-based CRC screening move Cologuard and SimpleScreen economics together.
• Defensive behaviour on 2026-07-17 — the Nasdaq fell 1.5% and the CNN sentiment gauge moved into its "Fear" zone in the session ABT closed at $100.68 on results.